The Open Public Health Journal,
Год журнала:
2023,
Номер
16(1)
Опубликована: Окт. 23, 2023
Backgrounds
and
Aims:
Since
the
start
of
SARS-CoV-2
pandemic,
healthcare
workers
have
been
at
elevated
risk
contracting
COVID-19.
Although
COVID-19
vaccines
contributed
to
eradication
of,
or
substantial
decreases
in,
incidence
lethal
diseases,
major
determinant
vaccine
hesitancy
is
a
fear
associated
adverse
effects.
Here,
we
performed
survey
assessing
reactogenicity
safety
BNT162b2
in
real-world
setting.
Methods:
Data
were
collected
from
March
1
June
14,
2021.
A
total
206
hospital
employees
undergoing
mRNA
vaccination
completed
survey.
These
received
questionnaire
collect
common
uncommon
effects
developing
2–6
days
after
second
dose
Pfizer-BioNTech
vaccine.
Results:
After
dose,
female
sex
was
found
be
with
higher
vaccine-related
severe
systemic
than
male
(odds
ratio
[OR]
3.116,
95%
CI
2.365–7.113).
We
also
observed
that
anti-SARS-CoV-2
receptor-binding
domain
titer,
determined
on
day
when
administered,
significantly
participants
those
without
such
(OR
1.017,
1.001–1.034).
Conclusion:
Our
study
suggested
healthy
had
three-fold
Further
research
warranted
determine
whether
high
RBD
titer
time
might
indicate
disproportionate
inflammatory
reaction
leading
findings
contribute
decrease
disappearance
hesitancy.
Archives of Clinical Infectious Diseases,
Год журнала:
2023,
Номер
18(5)
Опубликована: Дек. 6, 2023
Background:
This
study
aimed
to
investigate
the
incidence
and
clinical
characteristics
of
flare-ups
in
patients
with
systemic
lupus
erythematosus
(SLE)
following
immunization
inactivated
SARS-CoV-2
vaccines.
Methods:
In
this
cross-sectional
at
Imam
Hossein
Hospital's
Rheumatology
Clinic
(Iran),
we
investigated
72
SLE
remission
who
received
Sinopharm
BIBP
COVID-19
vaccine.
Their
post-vaccination
status
was
monitored
for
3
months
using
Systemic
Lupus
Erythematosus
Disease
Activity
Index
2000
(SLEDAI-2K)
checklist
by
an
internal
medicine
specialist.
Results:
Fourteen
(19.44%)
experienced
symptom
after
vaccination.
The
most
common
symptoms
were
arthritis
(64.29%)
skin
rash
(21.43%).
Age,
sex,
organ
involvement,
treatment
regimen
did
not
significantly
differ
between
those
without
recurrence
(P
>
0.05).
second
vaccine
dose
led
more
compared
first
(12.12%
vs.
8.33%,
P
<
0.001).
However,
severity
recurrence,
measured
SLEDAI-2K
score
=
0.763),
interval
from
vaccination
0.075)
2
groups.
Except
patients,
none
participants
required
hospitalization,
flare-up
effectively
managed
prednisolone
dosage
adjustments.
For
these
changed,
steroid
increased;
one
them
admitted
hospital,
other
on
outpatient
basis.
Conclusions:
low;
mild
require
except
1
patient
hospitalized
rituximab
due
vasculitis
flare.
These
findings
highlight
safety
underscore
importance
close
monitoring,
especially
dose.
Revista Argentina de Reumatología,
Год журнала:
2024,
Номер
35(1), С. 11 - 16
Опубликована: Март 26, 2024
Objetivos:
estudiar
los
efectos
secundarios
y
el
riesgo
de
exacerbación
la
enfermedad
después
vacunación
COVID-19
en
una
muestra
pacientes
con
lupus
eritematoso
sistémico
(LES).
Materiales
métodos:
este
estudio
retrospectivo
que
investigó
101
LES.
Se
determinó
actividad
mediante
Systemic
Lupus
Erythematosus
Disease
Activity
Index
(SLEDAI)
antes
dos
dosis
vacuna
contra
SAR-COv-2.
registraron
vacunación.
Resultados:
recibieron
misma
fueron
10,3%
para
CoronaVAc,
42,2%
Pfizer
47,3%
AstraZeneca.
detectaron
76,2%
mayoría
fue
leve/moderado.
Los
más
frecuentes
fueron:
dolor
local
(62,3%),
cefalea
(36,6%)
fatiga
(34,6%).
El
cambio
mediana
del
SLEDAI
primera
segunda
no
estadísticamente
significativa
(p=0,68).
Solo
4,1%
individuos
aumentó
≥
3
puntos.
Conclusiones:
bien
tolerada
segura
Modern Rheumatology,
Год журнала:
2024,
Номер
unknown
Опубликована: Ноя. 16, 2024
ABSTRACT
Objectives
We
studied
the
current
state
and
factors
associated
with
acceptance
or
hesitancy
of
booster
doses
coronavirus
disease
2019
(COVID-19)
vaccine
among
patients
autoimmune
rheumatic
diseases
(ARDs)
in
Japan.
Methods
A
single-centre
cross-sectional
survey
was
conducted
outpatients
ARDs
who
visited
Immuno-Rheumatology
Center
at
St.
Luke’s
International
Hospital
from
1
October
2023
to
30
November
2023.
investigated
patient
characteristics,
COVID-19
vaccination–related
status,
decision-making
preferences,
health-related
independent
vaccine.
Results
total
241
were
included
analyses,
198
(82.2%)
received
doses,
while
43
(17.8%)
did
not.
Older
age
[adjusted
odds
ratio
(aOR)
=
0.43,
95%
confidence
interval
(CI):
0.19,
0.95,
P
.037],
having
rheumatoid
arthritis
(aOR
0.41,
CI:
0.92,
.030),
a
physician
recommend
receiving
0.47,
0.23,
.035)
independently
doses.
The
main
reasons
for
regarding
concerns
about
adverse
reactions
long-term
safety.
Conclusions
Our
findings
could
help
physicians
counsel
their
promote
appropriate
decision-making.
Benha Journal of Applied Sciences,
Год журнала:
2022,
Номер
7(11), С. 83 - 92
Опубликована: Ноя. 1, 2022
The
majority
of
documented
cases
arthritis
occurred
between
2
and
4
weeks
following
the
discovery
COVID
positive.These
mostly
involved
minor
joints
hands.Rheumatoid
arthritis,
psoriatic
vasculitis,
systemic
sclerosis,
septic
post-covid
flares
preexisting
inflammatory
are
all
examples
post-Covid-19
arthritis.Patients
with
COVID-19
vaccination-related
new-onset
arthralgias,
joint
disease
flare-up,
bursitis
often
experience
swelling,
discomfort,
stiffness,
possibly
restricted
range
motion.Molecular
mimicry,
generation
specific
autoantibodies,
involvement
certain
vaccine
adjuvants
primary
processes
by
which
causes
autoimmune.The
purpose
this
paper
was
to
provide
a
summary
clarify
recent
developments
in
our
understanding
after
COVID-19.
The Open Public Health Journal,
Год журнала:
2023,
Номер
16(1)
Опубликована: Окт. 23, 2023
Backgrounds
and
Aims:
Since
the
start
of
SARS-CoV-2
pandemic,
healthcare
workers
have
been
at
elevated
risk
contracting
COVID-19.
Although
COVID-19
vaccines
contributed
to
eradication
of,
or
substantial
decreases
in,
incidence
lethal
diseases,
major
determinant
vaccine
hesitancy
is
a
fear
associated
adverse
effects.
Here,
we
performed
survey
assessing
reactogenicity
safety
BNT162b2
in
real-world
setting.
Methods:
Data
were
collected
from
March
1
June
14,
2021.
A
total
206
hospital
employees
undergoing
mRNA
vaccination
completed
survey.
These
received
questionnaire
collect
common
uncommon
effects
developing
2–6
days
after
second
dose
Pfizer-BioNTech
vaccine.
Results:
After
dose,
female
sex
was
found
be
with
higher
vaccine-related
severe
systemic
than
male
(odds
ratio
[OR]
3.116,
95%
CI
2.365–7.113).
We
also
observed
that
anti-SARS-CoV-2
receptor-binding
domain
titer,
determined
on
day
when
administered,
significantly
participants
those
without
such
(OR
1.017,
1.001–1.034).
Conclusion:
Our
study
suggested
healthy
had
three-fold
Further
research
warranted
determine
whether
high
RBD
titer
time
might
indicate
disproportionate
inflammatory
reaction
leading
findings
contribute
decrease
disappearance
hesitancy.
